Yes, risperidone is an antipsychotic. Specifically, it belongs to the second generation of antipsychotics, sometimes called “atypical” antipsychotics. It was first approved by the FDA in December 1993 under the brand name Risperdal, manufactured by Johnson & Johnson, and it remains one of the most widely prescribed medications in its class.
What “Second-Generation Antipsychotic” Means
Antipsychotics are broadly divided into two generations. The first generation, developed in the mid-20th century, works primarily by blocking dopamine activity in the brain. These older drugs are effective but notorious for causing movement-related side effects like muscle stiffness, tremors, and involuntary repetitive motions.
Second-generation antipsychotics like risperidone still block dopamine receptors, but they do so more loosely. They can detach from those receptors more quickly, which is thought to explain why they’re less likely to cause movement problems. More importantly, their effects come largely from blocking a specific serotonin receptor. This dual action on both dopamine and serotonin pathways is what distinguishes the newer generation from the older one and broadens the range of symptoms these drugs can treat.
How Risperidone Works in the Brain
Psychotic symptoms like hallucinations and delusions are linked to overactive dopamine signaling in certain brain pathways. Risperidone dampens that signaling, which helps reduce these “positive” symptoms of psychosis. At the same time, its serotonin-blocking activity appears to help with mood regulation and cognitive symptoms that dopamine blockade alone doesn’t fully address.
Risperidone also has some activating effect on a different type of serotonin receptor, which may contribute to its ability to improve mood and anxiety symptoms in some patients. This complex receptor profile is why it’s useful across several different psychiatric conditions, not just schizophrenia.
Conditions Risperidone Treats
Risperidone has FDA approval for three distinct conditions, each with its own dosing range:
- Schizophrenia in adults and adolescents aged 13 to 17. Adults typically start at 2 mg per day, with an effective range of 4 to 8 mg daily. Adolescents start lower, at 0.5 mg, with a recommended target of 3 mg per day.
- Bipolar mania in adults and in children and adolescents aged 10 to 17. Adults start at 2 to 3 mg per day, with efficacy demonstrated up to 6 mg. Younger patients start at 0.5 mg with a recommended target of 2.5 mg per day.
- Irritability associated with autism in children and adolescents aged 5 to 16. This includes aggression, self-injury, and severe tantrums. Doses are weight-based, starting at 0.25 mg per day for children under 20 kg and 0.5 mg for those over 20 kg.
The autism indication is notable because risperidone was one of the first medications specifically approved for behavioral symptoms in autistic children. It doesn’t treat autism itself but can significantly reduce the severity of disruptive behaviors that interfere with daily life and learning.
Common Side Effects
Like all second-generation antipsychotics, risperidone can cause metabolic changes. Weight gain is one of the most frequently reported side effects. It can also raise blood sugar and cholesterol levels, which is why regular monitoring is standard practice for anyone taking it long-term. Typical monitoring includes checking weight monthly, fasting blood sugar at baseline and three months, and cholesterol panels every three months during the first year.
While risperidone causes fewer movement-related side effects than older antipsychotics, it’s not free of them entirely. At higher doses especially, some people experience restlessness, stiffness, or tremor. Among the second-generation drugs, risperidone sits somewhere in the middle for this risk.
Risperidone is also known for raising levels of prolactin, a hormone normally involved in milk production. Elevated prolactin can cause missed periods, breast tenderness or enlargement, and sexual dysfunction in both men and women. This effect tends to be more pronounced with risperidone than with many other drugs in its class.
An Important Safety Warning
Risperidone carries an FDA black box warning, the most serious type of drug safety alert, regarding use in elderly patients with dementia-related psychosis. In an analysis of 17 placebo-controlled trials, elderly dementia patients treated with atypical antipsychotics had a death rate of about 4.5% over a typical 10-week trial, compared to 2.6% in those given a placebo. That translates to roughly 1.6 to 1.7 times the risk of death. Most of these deaths were cardiovascular (heart failure, sudden cardiac death) or related to infections like pneumonia. There was also a significantly higher rate of strokes and mini-strokes in treated patients. Risperidone is not approved for treating psychosis related to dementia.
How It Compares to Other Antipsychotics
Risperidone occupies a middle ground among second-generation antipsychotics. It tends to cause less weight gain than some alternatives in its class but more prolactin elevation. Its movement-related side effect risk is higher than some newer options but substantially lower than first-generation drugs, thanks to the way it binds loosely to dopamine receptors and releases quickly.
It’s available in several forms: standard tablets, orally dissolving tablets, liquid solution, and a long-acting injectable given every two weeks for patients who have difficulty taking daily medication. This range of options makes it one of the more versatile antipsychotics available. Generic versions are widely available, which also makes it one of the more affordable choices in its class.